Skip to main content
TNGX logo

TNGX · Tango Therapeutics, Inc. · Metrics

Track TNGX — free
$21.93 -0.78 (-3.43%)
Market Cap
$3.85B
Shares
169.46M
Volume · Nov 20 932.36K Avg daily vol (3M) 3.41M

TNGX metrics

70 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$22.71
Market cap
$3.85B

Price action

23 metrics
Price change (1W)
-8.6%
Price change (30D)
-15.8%
Price change (3M)
-3.4%
Price change (6M)
+5.0%
Price change (YTD)
+156.3%
Price change (1Y)
+174.1%
Trailing year
Price change (5Y)
+89.7%
52-week high
$32.90
52-week low
$8.29
Change from 52-week high
-31.0%
Change from 52-week low
+174.1%
Annualized volatility
101.5%
Annualized volatility (3M)
78.6%
Implied volatility (30D)
82.9%
IV rank (1Y)
17.7
IV percentile (1Y)
25.0
Beta
1.6
RSI (14D)
47.6
Price vs SMA 50
-3.3%
Price vs SMA 200
-1.7%
Avg volume (3M)
3.41M
Relative volume
0.5
Average dollar volume
$80.23M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
169.46M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.9
reciprocal yield 25.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$228.53M
Net income (TTM)
−$208.00M
Trailing 12 months
Diluted EPS (TTM)
$-1.37
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.52
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.39
Operating cash flow per diluted share (TTM)
$-1.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.02
Stock compensation per diluted share (TTM)
$0.38
Book value per share
$5.78

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
-530.6%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-400.0%
Shares change YoY
+47.7%
Year over year · more shares
Revenue CAGR (3Y)
+35.9%
Revenue CAGR (5Y)
+52.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-21.2%
Return on assets
-20.1%
Debt / equity
—
Current ratio
39.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
39.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$977.50M
Latest balance sheet
Cash & equivalents
$86.83M
Total assets
$1.03B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$150.09M
Capital expenditures (TTM)
$277,000
R&D (TTM)
$151.76M
SG&A (TTM)
—
Stock compensation (TTM)
$58.58M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
257
13F filer change QoQ
+10
Institutional ownership
126.0%
Conviction holders (share of 13F filers)
7.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.3%
Holder tenure
9.1
Price vs estimated holder cost
+56.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.5%

Short interest

3 metrics
Short interest
28.5%
Latest settlement · 9.7 days to cover
Days to cover
9.7d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.94M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1819133 CUSIP 87583X109 13F (30d) 267 filings 250 filers Visit website Investor relations